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Abstract 
 
Background: Xiao-Chai-Hu Tang (XCHT) is an extract of seven herbs with anticancer properties, but its mechanism 
of action is unknown. In this study, we evaluated XCHT-treated hepatocellular carcinoma (HCC) for anti-proliferative 
and pro-apoptotic effects.   
Materials and Methods: Using a hepatic cancer xenograft model, we investigated the in vivo efficacy of XCHT 
against tumor growth by evaluating tumor volume and weight, as well as measuring apoptosis and cellular proliferation 
within the tumor.  To study the effects of XCHT in vitro, we measured the cell viability of XCHT-treated Huh7 cells, as 
well as colony formation and apoptosis.  To identify a potential mechanism of action, the gene and protein expression 
levels of Bax, Bcl-2, CDK4 and cyclin-D1 were measured in XCHT-treated Huh7 cells.   
Results: We found that XCHT reduced tumor size and weight, as well as significantly decreased cell viability both in 
vivo and in vitro. XCHT suppressed the expression of the proliferation marker Ki-67 in HCC tissues and inhibited 
Huh7 colony formation. XCHT induced apoptosis in HCC tumor tissues and in Huh7 cells. Finally, XCHT altered the 
expression of Bax, Bcl-2, CDK4 and cyclin-D1, which halted cell proliferation and promoted apoptosis.  
Conclusion: Our data suggest that XCHT enhances expression of pro-apoptotic pathways, resulting in potent 
anticancer activity.  
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Introduction 
 
Hepatocellular carcinoma (HCC) is one of the top five cancers diagnosed worldwide [El-Serag and Rudolph, 
2007; Jemal et al, 2011].  HCC is the third leading cause of cancer-related deaths, and China will contribute close to 
half of the estimated 600,000 individuals who will succomb to the disease annually [Jemal et al, 2011; Sherman, 2005]. 
Surgical resection is the preferred treatment following HCC diagnosis, since removing the tumor completely offers the 
best prognosis for long-term survival.  This treatment is suitable for only 10-15% of patients with early-stage disease, 
since tumor resection may disrupt vital functions or structures if the tumor is large or has infiltrated into major blood 
vessels [Levin et al, 1995]. For patients with advanced stage HCC, chemotherapy is the best therapeutic option 
available.  Standard chemotherapeutic regimens can involve single agents or a combination of drugs such as 
doxorubicin, cisplatin or fluorouracil.  Late stage HCC develops drug resistance to standard chemotherapeutic 
combinations, and less than 20% of patients with advanced liver cancer will respond to these treatment regimens 
[Abou-Alfa et al, 2008]. Identification of more effective anticancer therapies is needed to provide alternatives to 
standard chemotherapeutic regimens, as well as treatments for drug resistant HCC.  
Complementary and alternative medicines (CAM) have received considerable attention in Western countries 
for their potential therapeutic applications [Xu et al, 2006; Cui et al, 2010]. Traditional Chinese medicine (TCM) has 
been used in the treatment of cancer for thousands of years in China and other Asian countries. These medicines have 
gained acceptance as alternative cancer treatments in the United States and Europe [Wong et al, 2001; Gai et al, 2008]. 
When TCM is combined with conventional chemotherapy, there is an increase in the sensitivity of tumors to 
chemotherapeutic drugs, a reduction in both the side effects and complications associated with chemotherapy or 
radiotherapy, and an improvement in patient quality of life and survival [Konkimalla and Efferth, 2008].  
Xiao-Chai-Hu-Tang (XCHT) is an extract of seven herbs: Bupleurum chinense (Chai-Hu), Pinellia ternata 
(Ban-Xia), Scutellaria baicalensis (Huang-Qin or Chinese skullcap root), Zizyphus jujube var. inermis (Da-Zao or 
jujube fruit), Panax ginseng (Ren-Shen or ginseng root), Glycyrrhiza uralensis (Gan-Cao or licorice root), and Zingiber 
officinale (Sheng-Jiang or ginger rhizome).  The formulation for XCHT was first recorded in Shang Han Za Bing Lun 
during the Han Dynasty, and the ancient methodology for preparing XCHT has been performed in China for thousands 
of years.  In TCM, XCHT has traditionally been used to treat a variety of Shaoyang diseases（including disorders of 
Zhao et al., Afr J Tradit Complement Altern Med., (2017) 14 (3): 231-241 
doi:10.21010/ajtcam.v14i3.25 
232 
 
the liver and gallbladder).  Common side-effects experienced with XCHT treatment include alternating chills and fever, 
but the medication is well-tolerated by the majority of patients.  The relatively low toxicity of XCHT is an important 
characteristic for potential use of this extract in combinatorial therapies.  Ancient scholars believed the mechanism of 
action of XCHT involved harmonizing the Shaoyang，where pathogens were eliminated through enhanced liver 
function and improved digestion.  More recently, XCHT has been reported to be effective as an anti-cancer agent, 
although the precise mechanism of its tumoricidal activity remains unclear [Zhu et al, 2005; Shiota et al, 2002; 
Watanabe et al, 2001; Yano et al, 1994; Kato et al, 1998; Liu et al, 1998; Mizushima et al, 1995]. To gain further 
insights into the mechanism of action of this ancient extract, we examined the anti-proliferative and pro-apoptotic 
activities of XCHT on HCC. 
 
Materials and Methods 
Materials and Reagents 
 
Dulbecco's Modified Eagle Medium (DMEM), fetal bovine serum (FBS), penicillin–streptomycin, trypsin-
EDTA and TriZol reagents were purchased from Life Technologies (Carlsbad, CA, USA). PrimeScript™ RT reagent 
Kit with gDNA Eraser was purchased from Takara BIO Inc. (Tokyo, Japan). TUNEL assay kit was purchased from 
R&D Systems (Minneapolis, MN, USA). BCA Protein Assay Kit was purchased from Tiangen Biotech Co., Ltd. 
(Beijing, China). Antibodies for Bax, Bcl-2, CDK4 and CyclinD1 were obtained from Santa Cruz Biotechnology, Inc. 
(Santa Cruz, CA). All other chemicals, unless otherwise stated, were obtained from Sigma-Aldrich (St. Louis, MO, 
USA). 
 
Preparation of Xiao-Chai-Hu-Tang (XCHT).   
 
The Xiao-Chai-Hu-Tang extract was prepared by boiling 7 authenticated herbs in distilled water: 24.0g 
Bupleurum chinense root (Chai-Hu), 9.0g Pinellia ternata tuber (Ban-Xia), 9.0g Scutellaria baicalensis root (Huang-
Qin), 9g Zizyphus jujube var. inermis fruit (Da-Zao or jujube fruit), 6g Panax ginseng root (Ren-Shen or ginseng), 5.0g 
Glycyrrhiza uralensis root (Gan-Cao or licorice), and 9.0g Zingiber officinale rhizome (Sheng-Jiang or ginger). The 
aqueous extraction was filtered and spray-dried. A stock solution of XCHT was prepared immediately prior to use by 
dissolving the XCHT powder in DMEM at a concentration of 250 mg/ml. The working concentrations of XCHT were 
obtained by diluting the stock solution in the culture medium. 
 
Cell Culture 
 
A human hepatoma cell line (Huh7) was purchased from Xiangya Cell Center (Hunan, China). Huh7 cells 
were grown in DMEM supplemented with 10% (v/v) FBS, 100 units/ml penicillin, and 100 μg/ml streptomycin. Huh7 
cells were cultured at 37˚C, in a 5% CO2 humidified environment. The cells were subcultured at 80-90% confluency.  
 
Animals 
 
 Male BALB /C athymic nude mice (with an initial body weight of 20–22 g) were obtained from SLAC 
Animal Inc. (Shanghai, China).  Animals were housed in standard plastic cages under automatic 12 h light/dark cycles 
at 23 °C, with free access to food and water. All animals were kept under specific pathogen-free conditions. The animal 
studies were approved by the Fujian Institute of Traditional Chinese Medicine Animal Ethics Committee (Fuzhou, 
Fujian, China). The experimental procedures were carried out in accordance with the Guidelines for Animal 
Experimentation of Fujian University of Traditional Chinese Medicine (Fuzhou, Fujian, China).  
 
In Vivo Xenograft Study 
 
Hepatocarcinoma xenograft mice were produced using Huh7 cells.  The cells were grown in culture, detached 
by trypsinization, washed, and resuspended in serum-free DMEM. Resuspended cells (4 × 106) mixed with Matrigel 
(1:1) were subcutaneously injected into the right flank of nude mice to initiate tumor growth. When tumor sizes reached 
3 millimeters in diameter, mice were randomly divided into two groups (n =10) and treated with XCHT (dissolved in 
saline) or saline daily by intraperitoneal injection. All treatments were given 5 days a week for 21 days. Body weight 
and tumor size were measured. Tumor size was determined by measuring the major (L) and minor (W) diameters with a 
caliper. The tumor volume was calculated according to the following formula: tumor volume = π/6×L×W2. At the end 
of the experiment, the mice were anaesthetized with ether and sacrificed by cervical vertebra dislocation. The tumors 
were then excised and weighed. and tumor segments were fixed in buffered formalin and stored at -80°C for molecular 
analysis. 
 
Assessment of Cell Viability by the MTT Assay.   
 
Cell viability was assessed by the MTT colorimetric assay. Huh7 cells were seeded into 96-well plates at a 
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density of 1x104 cells/well in 0.1 ml medium. The cells were treated with various concentrations (0, 0.5, 1.0, 1.5 
mg/ml) of XCHT for 24 h, 48 h and 72 h. At the end of the treatment, 100 µl of MTT (0.5 mg/ml in PBS) were added to 
each well, and the samples were incubated for an additional 4 h at 37˚C. The purple-blue MTT formazan precipitate 
was dissolved in 100 µl DMSO. The absorbance was measured at 570 nm using an ELISA reader (BioTek, Model 
ELX800, USA). 
 
Cell Morphology  
  
Huh7 cells were seeded into 6-well plates at a density of 2 ×105 cells/ml in 2 ml DMEM. The cells were treated with 0, 
0.5, 1.0, and 1.5 mg/mL of XCHT for 24 h. Cell morphology was observed using a phase-contrast microscope 
(Olympus, Japan), and the photographs were taken at a magnification of 200 ×.  
 
Detection of Apoptosis with Hoechst Staining.   
 
Huh7 cells were seeded into 12-well plates at a density of 1×105 cells/ml in 1 ml medium. After the cells were 
treated with XCHT for 24 h, apoptosis was visualized using the Hoechst staining kit as described in the manufacturer’s 
instructions. Briefly, at the end of the treatment, cells were fixed with 4% polyoxymethylene and then incubated in 
Hoechst solution for 5–10 min in the dark. Images were captured using a phase-contrast fluorescence microscope 
(Leica, Germany) at a magnification of 400×. 
 
Colony Formation  
 
Huh7 cells were seeded into 6-well plates at a density of 2x105cells/ml in 2 ml medium. After treatment with 
various concentrations (0, 0.5, 1.0, 1.5mg/ml) of XCHT for 24 h, the cells were collected and diluted in fresh medium 
in the absence of XCHT and then reseeded into 6-well plates at a density of 1x103 cells/well. Following incubation for 
8 days in a 37˚C humidified incubator with 5% CO2, the colonies were fixed with 10% formaldehyde, stained with 
0.01% crystal violet and counted. Cell survival was calculated by comparing the survival of compound-treated cells to 
the control cells (normalized to 100% survival). 
 
Apoptosis Detection in Hepatocarcinoma Tissues by TUNEL Staining.   
 
Six tumors were randomly selected from XCHT-treatment or control groups. Tumor tissues were fixed in 10% 
formaldehyde for 48 h, paraffin-embedded and then sectioned into 4- μm-thick slides. Samples were analyzed by 
TUNEL staining. Apoptotic cells were counted as DAB-positive cells (brown staining) in five arbitrarily selected 
microscopic fields at a magnification of 400×. TUNEL-positive cells were counted as a percentage of the total cells. 
 
Immunohistochemistry Analysis of Hepatocarcinoma Tissues 
 
Immunohistochemical staining for Ki-67 was performed as previously described. The sections were 
deparaffinized in xylene and hydrated through graded alcohols. Antigen retrieval was performed using heat treatment 
(placed in a microwave oven at 750 Watts for 7 minutes), in 10 mM sodium citrate buffer, pH 6.0. Sections were 
allowed to cool in the buffer at room temperature for 30 minutes, and the sections were then rinsed in deionised water 
three times for two minutes each. The endogenous peroxidase activity was blocked with 3% (v/v) hydrogen peroxide 
for 10 minutes. The sections were incubated with 1% bovine serum albumin in order to decrease non-specific staining 
and reduce endogenous peroxidase activity. The sections were then incubated with Ki-67 antibody (1:100 dilution), at 
4 C over night using a staining chamber. After rinsing three times in PBS, sections were incubated in biotinylated goat 
anti-rabbit IgG (Boshide Wuhan, China), followed by treatment with an avidin–biotin–peroxidase complex (Vector). 
Immunostaining was visualized by incubation in 3,3-diaminobenzidine (DAB) as a chromogen. Sections were 
counterstained with haematoxylin. The Ki-67 positive immunostaining was visualized using a Nikon Eclipse 50i 
microscope (40× objective). The evaluation of Ki-67 expression was analyzed in 5 different fields, and the mean 
percentage of Ki-67 positive staining was evaluated. To rule out any non-specific staining, PBS was used in place of 
the primary antibody as a negative control. 
 
RNA Extraction and RT-PCR Analysis 
 
 The expression of Bax, Bcl-2, CDK4 and CyclinD1 genes in HCC tissues or cells was analyzed by RT-PCR. 
Total RNA was isolated with TriZol Reagent according to the manufacturer’s instructions. 1 µg of total RNA was used 
to synthesize cDNA using the SuperScript II reverse transcriptase Kit (AMV) (TaKaRa,Tokyo, Japan).  The reaction 
contained RNA, selected primers, and 10µl of the RT-PCR master mix: 10 mM Tris–HCl (pH8.3), 50 mM KCl, 5 mM 
MgCl2, 1 unit/ µl RNase inhibitor, 0.25 unit/µl AMV reverse transcriptase, 2.5 ml random primer, and 1 mM each of 
dATP, dGTP, dCTP and dTTP. Reverse transcription was performed for 1 hour at 42℃. The obtained cDNA was used to 
determine the mRNA amount of Bax, Bcl-2, CDK4 and cyclin-D1 by PCR. GAPDH was used as an internal control. 
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Samples were analyzed by gel electrophoresis (1.5% agarose). The DNA bands were visualized using a gel 
documentation system (BioRad, Model Gel Doc 2000, USA).  
The sequences of the primers used for amplification of CDK4, CyclinD1, Bcl-2, Bax and GAPDH transcripts are as 
follows: CDK4 forward, 5'- CAT GTA GAC CAG GAC CTA AGC-3' and reverse, 5' -AAC TGG CGC ATC AGA TCC 
TAG-3'; cyclin-D1 forward, 5'-TGG ATG CTG GAG GTC TGC GAG GAA -3' and reverse, 5' - GGC TTC GAT CTG 
CTC CTG GCA GGC -3'; Bcl-2 forward, 5′-CAG CTG CAC CT GAC GCC CTT-3 and reverse, 5′-GCC TCC GTT 
ATC CTG GAT CC-3′; Bax forward, 5′-TGC TTC AGG GTT TCA TCC AGG-3′ and reverse, 5′-TGG CAA AGT AGA 
AAA GGG CGA-3′; GAPDH forward, 5′-GTC ATC CAT GAC AAC TTT GG-3′ and reverse, 5′-GAG CTT GAC AAA 
GTG GTC GT-3′. 
 
Western Blotting Analysis  
 
Four tumors were randomly selected from XCHT-treatment or control groups. Tumors were homogenized in 
nondenaturing lysis buffer and centrifuged at 14,000 × g for 15 min. Protein concentrations were determined by BCA 
protein assay. Huh7 cells (2.0 × 105 cells/ml) in 5ml medium were seeded into 25 cm2 flasks and treated with the 
indicated concentrations of XCHT for 24 h. Treated cells were lysed in mammalian cell lysis buffer containing protease 
and phosphatase inhibitor cocktails, and centrifuged at 14,000 × g for 15 min. Protein concentrations in cell lysate 
supernatants were determined by BCA protein assay. Equal amounts of protein from each tumor or cell lysate were 
resolved on 12% SDS-PAGE gels using 80 V for 2 h and transferred onto PVDF membranes. The membranes were 
blocked for 2 h with 5% nonfat milk and incubated with the desired primary antibody directed against Bax, Bcl-2, 
CDK4, Cyclin D1, or β-actin (all diluted 1:1000) overnight at 4°C. Appropriate HRP-conjugated secondary antibodies 
(anti-rabbit or anti-mouse; 1:2000) were incubated with the membrane for 1 h at room temperature, and the membranes 
were washed again in TBS-T followed by enhanced chemiluminescence detection. 
 
Statistical Analysis 
 
All data are shown as the mean of three measurements. The data were analyzed using the SPSS package for 
Windows (Version 11.5). Statistical analysis of the data was performed using the Student's t-test and ANOVA. 
Differences with P<0.05 were considered statistically significant. 
 
Results 
XCHT inhibits hepatocellular carcinoma (HCC) growth in vitro and in vivo.  
 
We evaluated the in vitro anti-cancer activity of XCHT on the human hepatocellular carcinoma cell line Huh7 
using the MTT assay. As shown in Figure 1A, treatment with 0.5-1.5 mg/ml of XCHT for 24, 48, or 72 reduced the 
viability of Huh7 cells by 17.91-26.27%, 44.01-77%, and 64.8-86.71% (P < 0.05) compared to untreated controls.  
These results indicate that XCHT inhibits the growth of Huh7 cells in both dose- and time-dependent manners. To 
verify these results, we evaluated the effect of XCHT on Huh7 cell morphology using phase-contrast microscopy. As 
shown in Figure 1B, untreated Huh7 cells appeared as densely packed and disorganized multilayers.  In contrast, many 
of the XCHT-treated cells were rounded, shrunken, and detached from adjacent cells, or floating in the medium. Taken 
together, these data demonstrate that XCHT inhibits the growth of Huh7 cells. 
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Figure 1: Effect of Xiao-Chai-Hu Tang (XCHT) on the viability and morphology of Huh7 cells. (A) Cell viability was 
determined by the MTT assay after Huh7 cells were treated with 0.5-1.5 mg/ml XCHT for 24, 48 or 72 h. The data 
were normalized to the viability of control cells (100%). Data are the averages with standard deviation (SD; error bars) 
from 3 independent experiments. The symbols (#), (*), and (﹠) indicate statistical significance compared to control 
cells (P<0.05), for each indicated timepoint. (B) The Huh7 cells were treated with the 0.5-1.5 mg/ml XCHT for 24 h, 
and morphological changes were observed using phase-contrast microscopy. The images were captured at a 
magnification of 200×. Images are representative of 3 independent experiments. 
To explore the anti-cancer activity of XCHT in vivo, we measured tumor volume and weight in HCC xenograft 
mice. As shown in Figure 2A and 2B, XCHT treatment significantly reduced both tumor volume and weight by Day 11 
post-treatment.  In contrast to tumors from the control group (293.37±19.36 mm3), XCHT treatment reduced tumor 
volume by 15.15% (201.5±27.83 mm3; P < 0.05). Tumor weight was reduced by 31.84% in XCHT-treated mice 
compared to control-treated mice (P < 0.05). Mice treated with XCHT demonstrated no changes in body weight during 
the course of the study, suggesting that XCHT treatment was relatively nontoxic to the animals (Figure 2C). Taken 
together, these data suggest that XCHT inhibits HCC growth both in vivo and in vitro, without apparent adverse effects. 
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Figure 2: Effect of XCHT on tumor growth in hepatocellular carcinoma (HCC) xenograft mice. After tumor 
development, the mice were given intra-gastric administration of 14.2 g /kg of XCHT or PBS daily for 21 days. Tumor 
volume (A), tumor weight (B), and body weight (C) were measured. Data shown are averages with SD (error bars) 
from 10 mice in each group (n = 10). * P 0.05, versus controls.  
 
XCHT inhibits HCC proliferation in vivo and in vitro 
 
One of the hallmarks of oncogenesis is unchecked cell proliferation, but the anti-proliferative activity of 
XCHT on hepatocarcinoma tumors was unknown. To measure the effect of XCHT on cell proliferation, we examined 
XCHT-treated tumors for a marker expressed by proliferating cell nuclei (Ki-67) using immunohistochemical staining 
(IHC).  As shown in Figure 3A , the percentages of Ki-67 positive cells in tumor tissues from control and XCHT-treated 
xenograft mice were 76.0 ± 9.6% and 51 ± 15.3%, respectively (P <0.05). To examine the anti-proliferative activity of 
XCHT in vitro, Huh7 cells were treated with 0.5-1.5 mg/ml of extract and colony formation was measured.  As shown 
in Figure 3B, treatment with increasing concentrations of XCHT for 24 h reduced the cell survival rate by 55.3%, 
69.8% and 92.8% compared to untreated controls (P < 0.05). These results suggest that XCHT can inhibit HCC cell 
proliferation both in vivo and in vitro. 
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Figure 3: Effect of XCHT on cell proliferation in HCC xenograft mice and Huh7 cells.  (A) Ki-67 assay in tumor 
tissues (400 ×). Data shown are averages with SD (error bars) from 6 individual mice in each group (n = 6). * P < 0.05, 
versus controls. (B) Huh7 cell colony formation assay. Data are averages with SD (error bars) from at least three 
independent experiments. *P < 0.01, versus control cells. 
 
XCHT induces apoptosis of hepatocellular carcinoma cells in vivo and in vitro.   
 
Apoptosis within HCC tumor tissues was visualized by IHC staining using the TUNEL assay. As shown in Fig 
4A, XCHT-treated mice had a significantly higher percentage of TUNEL-positive cells （82±15.3%) compared to the 
untreated control mice (47±9.6%), indicating the pro-apoptotic effect of XCHT in vivo . To visualize the pro-apoptotic 
activity in XCHT-treated Huh7 cells, we evaluated changes in nuclear morphology using the DNA-binding dye Hoechst 
33258. As shown in Fig 4B, XCHT -treated cells revealed condensed chromatin and a fragmented nuclear morphology, 
and these characteristics demonstrated typical apoptotic morphological features.  In contrast, untreated cell nuclei 
showed a less intense but homogenous staining pattern, indicative of proliferating cells. 
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Figure 4: Effect of XCHT on apoptosis in both HCC xenograft mice and Huh7 cells. (A) TUNEL assay in tumor 
tissues (400 ×). Data shown are averages with SD (error bars) from 6 individual mice in each group (n = 6). *P < 0.05, 
versus controls; (B) Huh7 cells were treated with 0.5-1.5 mg/ml XCHT for 24 h and stained with Hoechst 33258. 
Images were visualized using a phase-contrast fluorescence microscope. The images were captured at a magnification 
of 400×. Images are representative of 3 independent experiments. 
 
XCHT regulates the gene and protein expression correlated with apoptosis and proliferation in vivo and in vitro 
 
Very little is known regarding the mechanism of action of XCHT, or the pathways that this extract targets to 
generate its anti-proliferative and pro-apoptotic activities.  We examined the effect of XCHT treatment on the 
expression of correlated genes and proteins that are important regulators of apoptosis and proliferation using RT-PCR 
and western blotting. As shown in Fig 5A and B, XCHT significantly reduced both gene and protein expression of the 
anti-apoptotic factor Bcl-2 in HCC tumor tissues.  In contrast, the gene and protein expression of the pro-apoptotic 
factor Bax increased after XCHT treatment. XCHT treatment significantly decreased the mRNA and protein expression 
levels of CDK4 and cyclin-D1 compared to the control group (P < 0.05). Correlating with our in vivo data from HCC 
tissues, Huh7 cells treated with XCHT demonstrated a significant reduction in the mRNA and protein expression levels 
of Bcl-2, CDK4 and cyclin-D1, and an increase in the expression of Bax in vitro (Fig 6A and B).  Together these data 
suggest that XCHT promotes apoptosis and inhibits proliferation of HCC by increasing the pro-apoptotic Bax/Bcl-2 
ratio and modulating the expression of cell cycle-regulatory genes. 
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Figure 5: Effect of XCHT on the expression of Bcl-2, Bax, cyclin-D1 and CDK4 in HCC xenograft mice. (A) Four 
tumors were randomly selected from each group, and the mRNA or protein expression levels of Bcl-2, Bax, cyclin-D1, 
and CDK4 were determined by RT-PCR and Western blot analysis. GAPDH or β-actin were used as the internal 
controls. Data shown are representative samples. (B) Densitometric analysis of gene and protein expression levels. The 
data were normalized to the mean mRNA or protein expression levels of untreated control mice (100%). The symbols 
(*), (&), (#), and (§) indicate statistical significance versus controls (P 0.05), for Bax, Bcl-2, CDK4 or cyclin-D1. 
 
 
Figure 6: Effect of XCHT on the expression of Bcl-2, Bax, cyclin-D1 and CDK4 in Huh7 cells. The cells were treated 
with 0.5-1.5 mg/ml XCHT for 24 h. (A) The mRNA and protein levels of Bcl-2, Bax, CDK4 and cyclin-D1 were 
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determined using RT- PCR or western blotting. GAPDH or β - actin were used as the internal controls. The data are 
representative of three independent experiments. (B) Densitometric analysis of gene and protein expression levels. The 
data were normalized to the mean mRNA or protein expression of the untreated control cells (100%). The symbols (*), 
(&), (#), and (§) indicate statistical significance compared to control cells (P 0.05), for Bax, Bcl-2, CDK4 or cyclin-
D1. 
 
Discussion 
 
Xiao-Chai-Hu Tang (XCHT) is one of the most widely used Chinese herbal preparations, and it has long been 
used for the treatment of chronic liver diseases in China and other Asian countries. In the present study, we investigated 
its anti-tumor and anti-proliferative activities. Our findings suggest that XCHT could promote apoptosis and inhibit 
cellular proliferation in liver cancer. 
Cancer cells are characterized by an uncontrolled increase in cell proliferation and/or a reduction in apoptosis 
[Adams and Cory, 2007]. Cell cycle deregulation is a hallmark of tumor cells, and targeting the proteins that mediate 
critical cell cycle processes is an emerging strategy for the treatment of cancer [Stewart et al, 2003]. The G1/S 
transition is one of the two main checkpoints of the cell cycle [Nurse, 1994], which is responsible for initiation and 
completion of DNA replication. G1/S progression is strongly regulated by cyclin-D1, which exerts its function by 
forming an active complex with its CDK major catalytic partners (CDK4/6) [Morgan, 1995]. An unchecked or 
hyperactivated cyclin-D1/CDK4 complex often leads to uncontrolled cell division and malignancy [Harakeh et al, 2008; 
Kessel and Luo, 2000; Chen et al,1996; Zafonte et al, 2000]. Examination of cyclin-D1 and CDK4 expression levels 
during XCHT treatment demonstrated that XCHT suppresses the expression of both factors in HCC xenograft tissues 
and in Huh7 cells. 
Apoptosis is important for embryogenesis, tissue homeostasis and defence against pathogens. Notably, 
apoptotic resistance is one of the main causes of tumorigenesis and tumor drug resistance [Cory and Adams, 2002; Lee 
and Schmitt, 2003]. The Bcl-2 family plays a critical role in apoptotic regulation. Pro-apoptotic Bax promotes intrinsic 
apoptosis by forming oligomers in the mitochondrial outer membrane, which facilitates the release of the apoptogenic 
molecules.  In contrast, anti-apoptotic Bcl-2 blocks mitochondrial apoptosis by inhibiting the release and 
oligomerization of Bax [Leibowitz and Yu, 2010]. XCHT can induce apoptosis and overcome the apoptotic resistance 
of hepatocarcinoma cells in vitro and in vivo, which elevates the potential of this extract for development as an 
effective chemotherapy agent for treating HCC. 
 
Conclusion 
 
In conclusion, we demonstrate for the first time that XCHT can inhibit proliferation and induce apoptosis in 
liver cancer by regulating the expression of the Bcl-2 protein family and decreasing CDK4 and cyclin-D1 levels. 
Although the active ingredient and precise mechanism of action are not known, this research provides a starting point 
for exploring an XCHT-related HCC cancer therapy. 
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